Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.

BACKGROUND Positron emission tomography (PET) with the glucose analog F-18-fluorodeoxyglucose (FDG) is widely used in the diagnosis of neurodegenerative diseases. Guidelines recommend voxel-based statistical testing to support visual evaluation of the PET images. However, the performance of voxel-based testing strongly depends on each single preprocessing step involved. OBJECTIVE To optimize the processing pipeline of voxel-based testing for the prognosis of dementia in subjects with amnestic mild cognitive impairment (MCI). METHODS The study included 108 ADNI MCI subjects grouped as 'stable MCI' (n = 77) or 'MCI-to-AD converter' according to their diagnostic trajectory over 3 years. Thirty-two ADNI normals served as controls. Voxel-based testing was performed with the statistical parametric mapping software (SPM8) starting with default settings. The following modifications were added step-by-step: (i) motion correction, (ii) custom-made FDG template, (iii) different reference regions for intensity scaling, and (iv) smoothing was varied between 8 and 18 mm. The t-sum score for hypometabolism within a predefined AD mask was compared between the different settings using receiver operating characteristic (ROC) analysis with respect to differentiation between 'stable MCI' and 'MCI-to-AD converter'. The area (AUC) under the ROC curve was used as performance measure. RESULTS The default setting provided an AUC of 0.728. The modifications of the processing pipeline improved the AUC up to 0.832 (p = 0.046). Improvement of the AUC was confirmed in an independent validation sample of 241 ADNI MCI subjects (p = 0.048). CONCLUSION The prognostic value of voxel-based single subject analysis of brain FDG PET in MCI subjects can be improved considerably by optimizing the processing pipeline.

[1]  R. Buchert,et al.  Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers∗ , 2015, Alzheimer's & dementia.

[2]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[3]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[4]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[5]  Andrea Bergmann,et al.  Statistical Parametric Mapping The Analysis Of Functional Brain Images , 2016 .

[6]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[7]  Stewart Young,et al.  B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: Impact on voxel-based statistical single-subject analysis , 2010, NeuroImage.

[8]  Koen Van Laere,et al.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Albert Gjedde,et al.  Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson’s disease , 2009, NeuroImage.

[10]  N Wolfe,et al.  Functional Imaging Predicts Cognitive Decline in Alzheimer's Disease , 1996, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[11]  Luigi Gianolli,et al.  Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting , 2014, NeuroImage: Clinical.

[12]  F Fazio,et al.  Comparability of FDG PET studies in probable Alzheimer's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[14]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[15]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[16]  D E Kuhl,et al.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. , 1996, Radiology.

[17]  Karl J. Friston,et al.  Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. , 1998, European journal of nuclear medicine.

[18]  William Jagust,et al.  Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia , 2006, Alzheimer's & Dementia.

[19]  Harald Hampel,et al.  Fully automated atlas-based hippocampal volumetry for detection of Alzheimer's disease in a memory clinic setting. , 2015, Journal of Alzheimer's disease : JAD.

[20]  Jesper L. R. Andersson,et al.  How to Estimate Global Activity Independent of Changes in Local Activity , 1997, NeuroImage.

[21]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[22]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[23]  Clifford Goodman,et al.  Society of Nuclear Medicine , 1988 .

[24]  Karl Herholz,et al.  Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease , 2010, Expert review of neurotherapeutics.

[25]  Manuel Desco,et al.  Comparison of different methods of spatial normalization of FDG-PET brain images in the voxel-wise analysis of MCI patients and controls , 2013, Annals of Nuclear Medicine.

[26]  Fabrice Crivello,et al.  Age- and sex-related effects on the neuroanatomy of healthy elderly , 2005, NeuroImage.

[27]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[28]  Manuel Desco,et al.  Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.

[29]  Karl Herholz,et al.  Evaluation of a Calibrated 18F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment , 2011, The Journal of Nuclear Medicine.

[30]  Ralph Buchert,et al.  Adjusted Scaling of FDG Positron Emission Tomography Images for Statistical Evaluation in Patients With Suspected Alzheimer's Disease , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[31]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[32]  Kewei Chen,et al.  Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison , 2012, The Journal of Nuclear Medicine.

[33]  Alexander Hammers,et al.  SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging , 2009, NeuroImage.

[34]  Alan C. Evans,et al.  Searching scale space for activation in PET images , 1996, Human brain mapping.

[35]  R H Huesman,et al.  Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.

[36]  Satoshi Minoshima,et al.  Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.

[37]  A. Weindl,et al.  Voxel-Based Morphometry in Individual Patients: A Pilot Study in Early Huntington Disease , 2009, American Journal of Neuroradiology.

[38]  D. Silverman Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  T. Tasdizen,et al.  Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease , 2008, Alzheimer's & Dementia.

[40]  Paul M. Thompson,et al.  Characterizing Alzheimer's disease using a hypometabolic convergence index , 2011, NeuroImage.

[41]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[42]  J. Andersson,et al.  Accurate attenuation correction despite movement during PET imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  D. J. Wyper,et al.  Validation of Statistical Parametric Mapping (SPM) in Assessing Cerebral Lesions: A Simulation Study , 1999, NeuroImage.

[44]  G. Frisoni,et al.  Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer's Disease Consortium (EADC) project. , 2015, Journal of Alzheimer's disease : JAD.

[45]  Ron Kohavi,et al.  A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.

[46]  Alexander Hammers,et al.  Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 , 2008, Psychiatry Research: Neuroimaging.

[47]  Karl J. Friston,et al.  Human Brain Function , 1997 .

[48]  Karl J. Friston,et al.  A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia , 2014, Neuroinformatics.

[49]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[50]  Albert Gjedde,et al.  Normalization in PET group comparison studies—The importance of a valid reference region , 2008, NeuroImage.

[51]  Javier Arbizu,et al.  Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  Harald Hampel,et al.  Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. , 2015, Journal of Alzheimer's disease : JAD.

[53]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[54]  Paul J. Laurienti,et al.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.

[55]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.